XERS
Xeris Biopharma Holdings, Inc.
Drug Manufacturers - Specialty & Generic · Healthcare · United States
10.75
close · 2026-10-29
value
6
cheaper than peers6
quality
32
stronger fundamentals32
ranked against
Drug Manufacturers - Specialty & Generic
value
quality
41 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 4.34× | 28 |
| EV to EBITDA | 33.08× | 28 |
| price to book | 106.10× | 4 |
| forward P/E | 54.66× | 2 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| revenue growth | 28.7% | 82 |
| operating margin | 5.6% | 44 |
| debt to equity | 1987.2% | 4 |
3 of 4 measures available
Facts
| market cap | $2B |
| free cash flow | $52.5M |
| employees | 435 |
| first trade | 2018-06-21 |
| next earnings | 2026-11-05 |
| fundamentals updated | 2026-08-10 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | 0.00 | -0.37 | -0.45 | -0.70 |
| free cash flow | $27.9M | -$37.8M | -$49.3M | -$103.4M |
| net income | $554,000 | -$54.8M | -$62.3M | -$94.7M |
| revenue | $291.8M | $203.1M | $163.9M | $110.2M |
| unusual items | $0 | $1.7M | $2.4M | -$2.6M |